Article ; Online: Recent progress in NIR-II fluorescence imaging-guided drug delivery for cancer theranostics.
Advanced drug delivery reviews
2023 Volume 197, Page(s) 114821
Abstract: Fluorescence imaging in the second near-infrared window (NIR-II) has become a prevalent choice owing to its appealing advantages like deep penetration depth, low autofluorescence, decent spatiotemporal resolution, and a high signal-to-background ratio. ... ...
Abstract | Fluorescence imaging in the second near-infrared window (NIR-II) has become a prevalent choice owing to its appealing advantages like deep penetration depth, low autofluorescence, decent spatiotemporal resolution, and a high signal-to-background ratio. This would expedite the innovation of NIR-II imaging-guided drug delivery (IGDD) paradigms for the improvement of the prognosis of patients with tumors. This work systematically reviews the recent progress of such NIR-II IGDD-mediated cancer therapeutics and collectively brings its essence to the readers. Special care has been taken to assess their performances based on their design approach, such as enhancing their drug loading and triggering release, designing intrinsic and extrinsic fluorophores, and/ or overcoming biological barriers. Besides, the state-of-the-art NIR-II IGDD platforms for different therapies like chemo-, photodynamic, photothermal, chemodynamic, immuno-, ion channel, gas-therapies, and multiple functions such as stimulus-responsive imaging and therapy, and monitoring of drug release and therapeutic response, have been updated. In addition, for boosting theranostic outcomes and clinical translation, the innovation directions of NIR-II IGDD platforms are summarized, including renal-clearable, biodegradable, sub-cellular targeting, and/or afterglow, chemiluminescence, X-ray excitable NIR-IGDD, and even cell therapy. This review will propel new directions for safe and efficient NIR-II fluorescence-mediated anticancer drug delivery. |
---|---|
MeSH term(s) | Humans ; Precision Medicine ; Theranostic Nanomedicine/methods ; Neoplasms/diagnostic imaging ; Neoplasms/drug therapy ; Neoplasms/pathology ; Antineoplastic Agents/therapeutic use ; Optical Imaging/methods ; Nanoparticles/therapeutic use |
Chemical Substances | Antineoplastic Agents |
Language | English |
Publishing date | 2023-04-08 |
Publishing country | Netherlands |
Document type | Journal Article ; Review ; Research Support, Non-U.S. Gov't |
ZDB-ID | 639113-8 |
ISSN | 1872-8294 ; 0169-409X |
ISSN (online) | 1872-8294 |
ISSN | 0169-409X |
DOI | 10.1016/j.addr.2023.114821 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 2241: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.